Compare the evidence

Sources, findings and their limits
Source and designPopulation or scopeFindingLimits
Official Felinta label [1]Cat prolonged-release carbimazole tabletsPhenobarbital may reduce efficacy; intact tablets, consistent feeding relationship and clinical/laboratory follow-up matter.Product-specific instructions; no detailed pair mechanism or automatic dose correction.
Carney et al., 2016 — AAFP guideline [2]Feline hyperthyroidism and comorbid diseasePlaces treatment in the context of monitoring and kidney or cardiac comorbidity.Abstract reviewed; some recommendations rely on panel experience. Not a phenobarbital interaction experiment.

Can phenobarbital affect carbimazole treatment in cats?

Yes. Felinta's cat product information states that concomitant phenobarbital may reduce carbimazole clinical efficacy. This is a possible loss-of-effect warning; it does not predict every cat's response or specify a dose correction. [1]

Which formulation does the reviewed carbimazole information concern?

Felinta 10 mg prolonged-release tablets for cats. Its tablet-handling, feeding and follow-up instructions belong to that formulation. Different carbimazole products need their own product-information review. [1]

Why does the prolonged-release formulation matter?

Felinta tablets must not be broken or crushed because this affects their sustained-release property. An interaction warning does not override that formulation-specific instruction or authorize altering the tablet to make a dose adjustment. [1]

What follow-up information does the source consider relevant?

The label emphasizes individual clinical assessment with total thyroxine, full haematology and liver and kidney parameters at follow-up. These findings and the treatment history must be interpreted together; an interaction alert alone cannot select a regimen. [1]

Does the label mention other interactions worth raising?

Yes. The label advises against concurrent benzimidazole anthelmintics such as fenbendazole or mebendazole and discusses vaccination considerations. These are additional product-label context, not newly verified pairwise catalogue rules created by this article. [1]

What does the source say about carbimazole timing in relation to food?

Food enhances Felinta bioavailability, and the timing and relationship to feeding should remain consistent day to day. This administration instruction does not establish a food-based correction for the phenobarbital interaction. [1]

Evidence appraisal

Felinta is a prolonged-release carbimazole product. Its pharmacology section identifies carbimazole as a prodrug rapidly converted to thiamazole, also called methimazole. Its administration section says food enhances bioavailability and requires a consistent relationship to feeding. These points explain why the product and its administration history matter when thyroid control changes; they do not identify a food-based method for reversing the phenobarbital warning. [1]

The 2016 AAFP hyperthyroidism guideline addresses the thyroid disorder together with comorbid conditions, including chronic kidney and cardiac disease. Its abstract also states that some recommendations rely on panel experience where research or consensus is lacking. It is clinical context for follow-up, not a direct phenobarbital–carbimazole trial or a reason to assign the interaction a numerical probability. [2] [1]

Clinical interpretation and follow-up

Felinta specifies clinical assessment with TT4, full haematology and liver and kidney parameters. An isolated TT4 result supplies only part of that picture. Documenting intact tablet administration and consistency relative to food helps the veterinarian interpret treatment history alongside the findings. [1]

Separate a possible phenobarbital interaction from altered administration of the prolonged-release product and the cat's thyroid or comorbid disease course. These can coexist. A medication alert identifies one question for follow-up; it cannot attribute a change in thyroid control to a single cause. [1] [2]

Questions for veterinary review

Editorial discussion checklist for your veterinarian:

  • Confirm the cat's exact prolonged-release product and the presence of phenobarbital in its medication history.
  • Bring clinical response and recent veterinarian-requested laboratory results to the review.
  • Check anthelmintics and other concurrent treatments as well as the named pair; do not crush or alter tablets based on an interaction summary.

Catalogue review status and evidence limits

The catalogue records contain verified direct evidence (cat): a species-scoped official-label statement, not necessarily a controlled interaction trial. The linked label PDF was also checked for publication.

A verified warning does not establish an individual animal's outcome, a patient-specific dose or independent clinical review. No matching rule does not prove safety.

Evidence sources

Citation scope: official labels support the interaction warnings; research and guidelines provide separately identified context. Each citation shows its document version or literature type and review scope. Catalogue identifiers may refer to earlier versions; this article uses the linked label PDF. Repeated labels are not independent studies. Source URLs and product authorizations may change.

  1. VMD: Felinta 10 mg Prolonged-release Tablets for Cats — Summary of Product Characteristics

    Evidence type: Official product label. Revised December 2024. 4.8, interactions; 4.9, administration and follow-up; 5.1–5.2, pharmacology. Page 4, Page 5, Page 6, Page 7. Source checked: . Open official VMD source

  2. 2016 AAFP Guidelines for the Management of Feline Hyperthyroidism.

    Carney HC et al. J Feline Med Surg. 2016;18(5):400-416. Evidence type: Consensus guideline. Review scope: Abstract and bibliographic record. Source checked: . Open research source

Content responsibility: ZooDDI. For veterinary discussion, not diagnosis, prescribing or emergency care. No independent veterinary clinical review has been completed.

Check a complete medication regimen